Next Article in Journal
Is Brukinsa (Zanubrutinib) a Safer Bruton’s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis
Previous Article in Journal
Recent Advance in the Sample Pretreatments for Drug Analysis in Zebrafish
Previous Article in Special Issue
Impact of Fixed-Dose Combination Versus Single-Component Therapy for Benign Prostatic Hyperplasia-Related Urinary Symptoms on Persistence, Adherence, and Satisfaction in a Real-Life Setting
 
 
Article

Article Versions Notes

Pharmaceuticals 2026, 19(3), 466; https://doi.org/10.3390/ph19030466
Action Date Notes Link
article html file updated 12 March 2026 11:39 CET Original file https://www.mdpi.com/1424-8247/19/3/466/html
article supplementary file uploaded. 12 March 2026 11:37 CET - https://www.mdpi.com/1424-8247/19/3/466#supplementary
article pdf uploaded. 12 March 2026 11:37 CET Version of Record https://www.mdpi.com/1424-8247/19/3/466/pdf
article xml uploaded. 12 March 2026 11:37 CET Update https://www.mdpi.com/1424-8247/19/3/466/xml
article xml file uploaded 12 March 2026 11:37 CET Original file -
Back to TopTop